NDV-HXP-S-KP.2
Phase 2Biologic
NDV-HXP-S-KP.2 is one of 19 biologic programs targeting COVID-19. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Singulair
AstraZenecaPreclinical
Activella
Eli LillyPreclinical
Proventil
Mylan Pharmaceuticals IncPreclinical
Nitrostat
VViatris Specialty LLC
Preclinical
SARS-COV-2 VACCINE
ModernaPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Statins
SanofiPreclinical
NDV-HXP-S-KP.2
CCastleVax Inc.
Phase 2
Antihypertensive Agents
NNational Heart, Lung, and Blood Institute (NHLBI)
Preclinical
Conventional
PPopulation Health Research Institute
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NDV-HXP-S-KP.2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- CCastleVax Inc.